Taisho Pharmaceutical Co., Ltd.: Phase 3 study closed enrollment, 34 enrolled (Hyperphosphatemia Patients on Hemodialysis)
Taisho Pharmaceutical Co., Ltd.: Phase 3 study closed enrollment, 34 enrolled (Hyperphosphatemia Patients on Hemodialysis). Its enrollment of 34 is below the median of 80 (22nd percentile). Dated 30 days ago, it is in the active follow-up window. Score 65/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 34 · 22th percentile of 8,879 ClinicalTrialStartPulse records · 0.4x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Taisho Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis |
| NCT ID | NCT07548840 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Hyperphosphatemia Patients on Hemodialysis |
| Intervention types | drug |
| Target enrollment | 34 |
| Site countries | Japan |
| Posted | 2026-04-23 |
| Planned start | 2026-05-08 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-06 |
| enrollment percentile | 22th of 8,879 (median 80, 0.4x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Taisho Pharmaceutical Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Taisho Pharmaceutical Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-06
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Taisho Pharmaceutical Co., Ltd. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Taisho Pharmaceutical Co., Ltd.'s enrollment: 22nd percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
65 / 100 Score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
What is the ClinicalTrialStartPulse record for Taisho Pharmaceutical Co., Ltd.?
Taisho Pharmaceutical Co., Ltd.'s Phase 3 study (NCT07548840) in Hyperphosphatemia Patients on Hemodialysis, first posted 2026-04-23: enrollment closed (active, not recruiting) (2026-10-06), in an update posted 2026-10-06.
How does Taisho Pharmaceutical Co., Ltd. compare to other ClinicalTrialStartPulse records?
Its enrollment of 34 is below the median (22th percentile); smaller records often move faster and face less competition. It is 30 days old, still within a typical 45-day follow-up window.
Taisho Pharmaceutical Co., Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Taisho Pharmaceutical Co., Ltd. | NONUS | 34 | 22nd | 2026-10-06 |
| Janssen-Cilag Ltd. | US | 120 | 65th | 2026-11-03 |
| NervGen Pharma | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 159 | 72nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Taisho Pharmaceutical Co., Ltd. and peer phase 3 records
Get new ClinicalTrialStartPulse records like Taisho Pharmaceutical Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.